FDA approves a Kite Oncology labeling update for CAR-T therapy Yescarta (axicabtagene ciloleucel), removing a previous limitation on its use in patients with relapsed or refractory primary central nervous system lymphoma.
FDA pledges to move quickly against companies that mass-market “illegal copycat drugs” by portraying them as equivalent to agency-approved medicines, commissioner Marty Makary says in a social media post, presumably signaling a tougher enforcement posture against compounded products like GLP-1 drugs for obesity.
